Association between DNA Methylation of the BDNF Promoter Region and Clinical Presentation in Alzheimer's Disease.
Association between DNA Methylation of the BDNF Promoter Region and Clinical Presentation in Alzheimer's Disease.
复制标题
DOI:
10.1159/000375367
复制
发表时间:
2015-01
影响因子:
2.3
通讯作者:
Nakayama K
中科院分区:
文献类型:
--
作者:
Nagata T;Kobayashi N;Ishii J;Shinagawa S;Nakayama R;Shibata N;Kuerban B;Ohnuma T;Kondo K;Arai H;Yamada H;Nakayama K
In the present study, we examined whether DNA methylation of the brain-derived neurotrophic factor (BDNF) promoter is associated with the manifestation and clinical presentation of Alzheimer's disease (AD). Of 20 patients with AD and 20 age-matched normal controls (NCs), the DNA methylation of the BDNF promoter (measured using peripheral blood samples) was completely analyzed in 12 patients with AD and 6 NCs. The resulting methylation levels were compared statistically. Next, we investigated the correlation between the DNA methylation levels and the clinical presentation of AD. The total methylation ratio (in %) of the 20 CpG sites was significantly higher in the AD patients (5.08 ± 5.52%) than in the NCs (2.09 ± 0.81%; p < 0.05). Of the 20 CpG sites, the methylation level at the CpG4 site was significantly higher in the AD subjects than in the NCs (p < 0.05). Moreover, the methylation level was significantly and negatively correlated with some neuropsychological test subscores (registration, recall, and prehension behavior scores; p < 0.05). These results suggest that the DNA methylation of the BDNF promoter may significantly influence the manifestation of AD and might be associated with its neurocognitive presentation.